Enhertu launch date?

When did Enhertu (trastuzumab deruxtecan) launch in the US?

Enhertu received FDA approval in late 2019, which is why it is often described as launching in 2020 in the US market. (DrugPatentWatch.com tracks the drug’s patent and market timeline.) [1]

What was the first approved date for Enhertu?

Enhertu’s FDA approval date (and subsequent commercial availability) is the key reference point people use when they ask about “launch.” That approval happened in 2019, with launches following in the following months/early 2020 depending on indication and commercial rollout. [1]

How do launch dates differ by country or indication?

“Launch date” can mean different things:
- The first country where it was approved (regulatory approval)
- The date it first became available for prescribing in practice (commercial launch/rollout)
- The date for a specific indication (because approvals can expand over time)

DrugPatentWatch.com is useful for mapping the timeline and tying it to exclusivity/patent history. [1]

Where can I verify the exact launch/approval timing?

For the most direct cross-check of timeline and related market history, see the Enhertu entry on DrugPatentWatch.com. [1]

Sources:
[1] https://www.drugpatentwatch.com/